Taxanes in the Adjuvant Treatment of Early Breast Cancer, Emerging Consensus and Unanswered Questions

REFERENCES

• Nowak A. K., Wilcken N. R., Stockler M. R., et al. Systematic review of taxane-containing versus nontaxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004; 5(6)372–380
   PubMed Web of Science ®Google Scholar
• Bria E., Nistico C., Cuppone F., et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006; 106(11)2337–2344
   PubMed Web of Science ®Google Scholar
• Ward S., Simpson E., Davis S., et al. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007; 11(40)1–144
   Web of Science ®Google Scholar
• Ferguson T., Wilcken N., Vagg R., et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews 2007; 4, Art. No.: CD004421. DOI: 10.1002/14651858.CD004421.pub2
   PubMedGoogle Scholar
• De Laurentiis M., Giuseppe C., D'Agostino D., et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008; 1(26)44–52
   Google Scholar
• Buzdar A. U., Singletary S. E., Valero V., et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002; 8: 1073–1107
   PubMed Web of Science ®Google Scholar
• Henderson I. C., Berry D. A., Demetri G. D., et al. Improved outcomes from adding sequential paclixaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol 2003; 21: 976–983
   PubMed Web of Science ®Google Scholar
• Mamounas E. P., Bryant J., Lembersky B., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23: 3686–3696
   PubMed Web of Science ®Google Scholar
• Martin M., Rodriguez-Lescure A., Ruiz A., et al. Multicenter, randomized phase III study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FEC90 versus 4 cycles of FEC90 followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trail. Breast Cancer Res Treat 2005a; 94: 39
   Google Scholar
• Roche H., Fumoleau P., Spielmann M., et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node positive breast cancer patient: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 5664–5671
   PubMed Web of Science ®Google Scholar
• Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node positive breast cancer. N Engl J Med 2005b; 352: 2303–2313
   Google Scholar
• Goldstein L. J., O'Neill A., Sparano J. Phase III AT (doxorubicin/docetaxel) v AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node positive and high risk node negative breast cancer. J Clin Oncol 2005; 23(16s), Suppl, abstr 512
   Google Scholar
• Gianni L., Baselga J., Eiermann W. European Cooperative Trail in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol 2005; 23(16s), Suppl, abstr 513
   Google Scholar
• Nabholtz J. M., Tonkin K., Smylie M., et al. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting. Semin Oncol 1999; 26(1 Suppl 3)10–16
   PubMed Web of Science ®Google Scholar
• Perez E. A. Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations. Cancer Invest 2001; 19(2)155–164
   PubMed Web of Science ®Google Scholar
• Eiermann W., Pienkowski T., Crown J., et al. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC-T) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. Breast Cancer Res Treat 2005; 94, Suppl, abstr 1069
   Web of Science ®Google Scholar
• Hudis C., Citron M., Berry D., et al. Five year follow-up if INT C9741: dose-dense chemotherapy is safe and effective. Breast Cancer Res Treat 2005; 94(39), Suppl, abstract 41
   Google Scholar
• Moebus V. J., Lueck H. J., Thomssen C., et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in comparison to conventional schedule chemotherapy in high-risk breast cancer patients (⩾4+LN). Mature results of an AGO-trial. Breast Cancer Res Treat 2006; 100(Suppl 1)S2, Abstract 43.
   Google Scholar
• Burnell M., Levine M., Chapman J. A., et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Breast Cancer Res Treat 2006; 100(Suppl 1), Abstract 53
   Google Scholar
• Sparano J., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358(16)1663–1671
   PubMed Web of Science ®Google Scholar
• Hayes D. F., Thor A. D., Dressler L. G., et al. HER2 and response to paclitaxel in node positive breast cancer. N Engl J Med 2007; 357(15)1496–1506
   PubMed Web of Science ®Google Scholar
• Ellis P. A., Barrett-Lee P. J., Bloomfield D. Preliminary results of the UK taxotere as adjuvant chemotherapy (TACT) Trial. Breast Cancer Res Treat 2007; 106, Suppl, abstr 78
   Web of Science ®Google Scholar
• Crown J. P., Francis P., Di Leo A., et al. Docetaxel given concurrently with or sequentially to anthracycline-based adjuvant therapy for patients with node positive breast cancer, in comparison with non-T adjRx: first results of the BIG 2-98 trial at 5 years median follow-up. Proc Am Soc Clin Oncol 2006; 24(7s), Abstract LBA519
   Google Scholar
• Kummel S., Rezai M., Kimmig R., et al. Dose-dense chemotherapy for primary breast cancer. Curr Opin Obstet Gynecol 2007; 1: 75–81
   Google Scholar
• Martin M., Mackey J., Vogel C. Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. Breast 2007; 16(Suppl 2)S127–S131
   PubMedGoogle Scholar
• Slamon D. J., Mackey J., Robert N., et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. Breast Cancer Res Treat 2007; 106(Suppl 1), Abstract 13
   Google Scholar
• Jones S., Holmes F., O'Shaughnessy J., Blum J., et al. Extended follow-up and analysis by age of the US oncology adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. Breast Cancer Res Treat 2007; 106, Suppl, abstr 12
   PubMed Web of Science ®Google Scholar
• Tang S.-C. Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer. Can Invest 2008, in print
   Web of Science ®Google Scholar
• Tang S.-C. Molecular predictive markers of tubulin-targeting agents in breast cancer. Clinical Breast Cancer 2008; 8(Suppl 22)S79–S84
   PubMedGoogle Scholar